Meta in Q2 2026 13Fs: Pershing and Appaloosa Buy, Baillie Gifford and Coatue Sell

When the Q2 2026 13F filings landed, most of the attention went to consensus trades. Meta Platforms is a more interesting case: some of the best-known concentrated funds were buying aggressively while others were cutting, all in the same quarter. A stock with this much disagreement among sophisticated holders is a good test of how to read 13F data honestly.

The Split in Numbers

According to a Q2 2026 overlap analysis of ten large funds, Meta had buyers and sellers on both sides. On the buying side, Pershing Square added roughly 20% to its position and Appaloosa, David Tepper's fund, raised its share count by about 55%. On the selling side, Baillie Gifford trimmed about 22% and Coatue cut about 10%. Atreides Management also disclosed a new call option position valued around $680 million.

That is a rare mix: a value-oriented concentrated investor, a macro-minded distressed specialist, a long-duration growth manager, and a crossover tech fund all reaching different conclusions on one ticker.

Why Smart Money Can Disagree

Each fund is solving a different problem. Pershing Square runs a concentrated book and tends to favor businesses with durable cash flows, so adding to Meta fits its toll-booth style. Appaloosa has been rotating toward large-cap quality and AI beneficiaries, and a 55% increase suggests Meta now sits higher in Tepper's conviction ranking.

Baillie Gifford and Coatue are growth-oriented, and trimming a mega-cap that has already re-rated is often about position sizing and funding other ideas rather than a bearish call. A 10% trim from a fund that still holds a large stake is not an exit. Reading a reduction as a "sell signal" is one of the most common 13F mistakes.

The Options Wrinkle

The $680 million call position from Atreides is a reminder that a 13F shows options exposure only as notional value on the underlying shares, not the premium paid or the real risk. A call position can be a leveraged bullish bet, a hedge against a short elsewhere, or a cheap way to get upside exposure without tying up capital. Without the rest of the fund's book you cannot tell which. We covered the mechanics in our post on reading option lines in a 13F.

Using This on InvestorLens

The practical question is whether a split like this has any signal. Three checks help.

First, look at size relative to the portfolio. A 20% add to a position that is 15% of a fund is a very different statement than a 55% add to a position that is 1% of a fund. Use the investor pages to see position weights, not just share counts.

Second, check the direction of the biggest holders over time. The flow page shows net institutional buying and selling, which helps separate a one-quarter rebalance from a multi-quarter trend.

Third, see who else holds the name. The overlap tool shows how many tracked funds own a stock and how crowded it is. A stock with heavy overlap and a split in direction is usually a name where the debate is about price, not about the business.

What to Watch Next

The Q3 2026 filings, due in mid-November, will show whether the Meta buyers kept adding or whether the sellers' trims became exits. Stocks that sit in the middle of a genuine disagreement often resolve in one direction over a couple of quarters, and the second filing matters more than the first.

It is also worth checking the macro consensus page to see how the broader positioning backdrop looks, since a mega-cap like Meta is often traded as a proxy for the AI and advertising cycle rather than purely on company fundamentals.

The Takeaway

Disagreement is information, but it is not a verdict. When respected investors split on a stock, the useful move is to understand why each is on their side, match that logic against your own time horizon, and remember that 13F data is a lagging snapshot of positions as of June 30. Meta in Q2 2026 is a clean example of why the holder's style matters at least as much as the direction of the trade.

---

Data sourced from public SEC 13F filings. Educational research only — not investment advice.